De Novo Backs VitreoRetinal

VitreoRetinal Technologies, an Irvine, California-based ophthalmic-drug company, has raised $9 million in a Series A funding from De Novo Ventures, reports VentureWire (vw). www.vitreoretinaltech.com

Share this